Recombinant Human IGF-BP5

Description :
FAQ COA 已发表文献 IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa, cysteine-rich, secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts, and osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5-overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition, and retarded muscle development. Recombinant Human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues. Product Properties Synonyms Human IGF-BP5 Accession P24593 GeneID 3488 Source E.coli-derived HumanIGF-BP5 protein,Leu21-Glu272. Molecular Weight Approximately 28.6 kDa. AA Sequence LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC KPSRGRKRGI CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 96% by SDS-PAGE and HPLC analyses. Biological Activity Fully biologically active when compared to standard. The ED50as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4 g/mL, corresponding to a specific activity of > 2500 IU/mg in the presence of 15 ng/mLof rHuIGF-II. Endotoxin 0.1 EU per 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered concentrated solution in 10 mM Sodium Citrate, pH 3.0. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20 C. Further dilutions should be made in appropriate buffered solutions.